Hebei to carry out epidemic prevention medicine and equipment to ensure quality, supply and price stability and to combat illegal special action

Read Time:3 Minute, 8 Second

On December 30, 2022, the Hebei Provincial Market Supervision Bureau and the Provincial Drug Administration jointly issued a notice to implement the decision of the Party Central Committee and the State Council to prevent and control the epidemic and the specific requirements of the provincial government, and decided that from now until the end of March 2023, the province will carry out special actions to ensure the quality and stable price of epidemic prevention medicine and combat violations. Special action to “four types of drugs” and antigen detection reagents as the focus, will be an in-depth investigation of the risk of hidden dangers, strengthen supervision and inspection, and strictly investigate and deal with counterfeiting, price gouging, hoarding and false propaganda and other illegal and illegal behavior, to protect the needs of the masses with drugs and firearms and safety, and effectively maintain the epidemic prevention drugs and firearms market order.

According to the action plan, market supervision departments at all levels will carry out special actions in seven aspects to ensure quality, supply, stable price and strict law enforcement, and take the initiative to strengthen coordination and linkage with relevant departments such as health, industry and information, public security and medical insurance to enhance the working synergy.

Strengthen the quality control of the production of epidemic prevention drugs. Supervise enterprises to do a good job of quality control of incoming raw materials, strictly investigate and deal with irregularities in the organization of production, and improve the efficiency of enterprise change registration audit. Supervise enterprises to do a good job of factory release. Supervise the holders of drug marketing licenses (drug manufacturers) to effectively implement the main responsibility for quality and strengthen the whole process of quality traceability management.

Strictly monitor the quality of new coronavirus vaccines and epidemic prevention drugs in circulation. Focus on the purchase and sales channels, cold chain protection, storage and transportation management, information traceability and network sales, and urge enterprises to fulfill their main responsibility for drug quality and social responsibility. Supervise and guide retail pharmacies to actively play their social responsibility, so that they can “open as many stores as possible”, conscientiously implement the system of licensed pharmacists on duty, and provide pharmacy services for the safe and reasonable use of drugs.

Strengthen the quality control of epidemic prevention medical devices. Prevent unqualified raw materials from entering the production process and unqualified products from entering the market. Continuously strengthen the monitoring and disposal of information on network transactions of epidemic prevention and control medical devices.

Strengthen the monitoring of adverse drug and medical device reactions for epidemic prevention and control. Strengthen the monitoring, analysis and evaluation of relevant adverse drug and medical device reactions (events).

Fully guarantee the orderly production and stable market supply of epidemic prevention and control medicine and medical devices. Guarantee the orderly supply of new coronavirus epidemic prevention and control medicine and equipment from the source to meet the needs and safety of the public with medicine and equipment. Take effective measures to ease the tension and ensure the accessibility of epidemic prevention ordnance.

Intensify the inspection of unfair competition and price violations. Focus on checking the sale of goods at extra price, charging unspecified fees, not marking prices according to regulations; fabricating and spreading information about price increase, compulsory tying; and raising prices unreasonably and substantially.

Strictly and quickly investigate and deal with illegal and irregular behavior. Crack down on substandard, jerry-built, fabricated data and other illegal acts. Crack down on the failure to obtain drug production and operation qualifications, approval documents and over the scope of production and operation activities. Crack down on hoarding, price gouging, price fraud, trademark infringement, patent counterfeiting, counterfeit confusion, false propaganda and false advertising and other illegal acts.